Great Point Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Great Point Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-150,000	Closed	-$10.4M	–	41
2024 Q1	$10.4M	Buy	150,000 +39,393	+36%	+$2.71M	1.62%	24
2023 Q4	$7.92M	Sell	110,607 -114,393	-51%	-$6.58M	1.35%	25
2023 Q3	$11.7M	Buy	+225,000	New	+$13.1M	2.13%	17
2023 Q2	–	Sell	-70,371	Closed	-$3.81M	–	54
2023 Q1	$3.81M	Buy	+70,371	New	+$3.4M	0.75%	33
2016 Q3	–	Sell	-100,000	Closed	-$3.88M	–	48
2016 Q2	$3.88M	Buy	+100,000	New	+$3.59M	1.11%	23

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's ITCI Position: Q2 2024 in Review

Great Point Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 150,000 shares — an estimated $10.4M sold.

Great Point Partners first reported a position in ITCI in Q2 2016 and held it in 5 quarters. The position peaked at $11.7M in Q3 2023. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Great Point Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
Great Point Partners sold 150,000 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $10.4M.
Great Point Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 5 quarters.
Great Point Partners's Intra-Cellular Therapies Inc. position peaked at $11.7M in Q3 2023.
376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Great Point Partners's 13F filing for Q2 2024, filed 14 Aug 2024.